EE9900607A - Imidasopürimidiinid ja imidasopüridiinid neuroloogiliste häirete käitlemiseks - Google Patents

Imidasopürimidiinid ja imidasopüridiinid neuroloogiliste häirete käitlemiseks

Info

Publication number
EE9900607A
EE9900607A EEP199900607A EEP9900607A EE9900607A EE 9900607 A EE9900607 A EE 9900607A EE P199900607 A EEP199900607 A EE P199900607A EE P9900607 A EEP9900607 A EE P9900607A EE 9900607 A EE9900607 A EE 9900607A
Authority
EE
Estonia
Prior art keywords
imidazopyrimidines
imidazopyridines
treatment
neurological disorders
neurological
Prior art date
Application number
EEP199900607A
Other languages
English (en)
Inventor
Georgios Arvanitis Argyrios
G. Wilde Richard
Bakthavatchalam Rajagopal
Peter Beck James
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE9900607A publication Critical patent/EE9900607A/et
Publication of EE04280B1 publication Critical patent/EE04280B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP199900607A 1997-07-03 1998-07-02 Imidasopürimidiinid ja imidasopüridiinid neuroloogiliste häirete käitlemiseks EE04280B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5162897P 1997-07-03 1997-07-03
US8066598P 1998-04-03 1998-04-03
PCT/US1998/013913 WO1999001454A1 (en) 1997-07-03 1998-07-02 Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
EE9900607A true EE9900607A (et) 2000-08-15
EE04280B1 EE04280B1 (et) 2004-04-15

Family

ID=26729655

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900607A EE04280B1 (et) 1997-07-03 1998-07-02 Imidasopürimidiinid ja imidasopüridiinid neuroloogiliste häirete käitlemiseks

Country Status (20)

Country Link
US (3) US6143743A (et)
EP (1) EP0994877A1 (et)
JP (1) JP2002507996A (et)
KR (1) KR20010014431A (et)
CN (1) CN1268137A (et)
AR (1) AR016307A1 (et)
AU (1) AU746706B2 (et)
BR (1) BR9810508A (et)
CA (1) CA2294117A1 (et)
EE (1) EE04280B1 (et)
HR (1) HRP980375A2 (et)
HU (1) HUP0100179A3 (et)
IL (1) IL133800A0 (et)
MY (1) MY132871A (et)
NO (1) NO316119B1 (et)
NZ (1) NZ502642A (et)
PL (1) PL337888A1 (et)
SK (1) SK179899A3 (et)
TW (1) TW589309B (et)
WO (1) WO1999001454A1 (et)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130397A (en) * 1996-12-11 2005-11-20 Aventis Pharma Inc Preparation of Ä1S-Ä1alpha,2beta,3beta,4alpha (S*)ÜÜ-4-Ä7-ÄÄ-3-chloro-2-thienyl)methylÜpropylÜaminoÜ-3H-imidazo Ä4,5-BÜpyridin-3-ylÜ-N-ethyl-2,3 dihydroxycyclopentane carboxamide
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6365589B1 (en) * 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
CN100340559C (zh) * 1998-12-23 2007-10-03 布里斯托尔-迈尔斯斯奎布药品公司 作为凝血因子xa抑制剂的含氮杂双环
US6271380B1 (en) * 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CA2392992A1 (en) * 1999-12-17 2001-06-21 Dupont Pharmaceuticals Company Imidazopyrimidinyl and imidazopyridinyl derivatives
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US6589952B2 (en) 2000-07-14 2003-07-08 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
KR20040034594A (ko) 2001-01-26 2004-04-28 브리스톨-마이어스스퀴브컴파니 코르티코트로핀 방출 인자 억제제로서의 이미다졸릴 유도체
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
JP4549630B2 (ja) 2001-03-13 2010-09-22 ブリストル−マイヤーズ スクイブ ファーマ カンパニー コルチコトロピン放出因子受容体リガンドとしての、４−（２−ブチルアミノ）−２，７−ジメチル−８−（２−メチル−６−メトキシピリド−３−イル）ピラゾロ−［１，５−ａ］−１，３，５−トリアジン、その鏡像異性体および薬学的に許容できる塩類
PL214231B1 (pl) 2001-04-27 2013-07-31 Eisai R & D Man Co Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie
US7205306B2 (en) 2001-05-14 2007-04-17 Bristol-Myers Squibb Pharma Company Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
AU2002354575A1 (en) 2001-07-12 2003-01-29 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
AU2002340405A1 (en) 2001-11-20 2003-06-10 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
EP1474425B9 (en) 2002-01-07 2008-07-02 Eisai Co., Ltd. Deazapurines and uses thereof
CA2478715A1 (en) 2002-03-13 2003-09-25 Pharmacia & Upjohn Company Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
US6884880B2 (en) * 2002-08-21 2005-04-26 Ash Stevens, Inc. Process for the preparation of 9-β-anomeric nucleoside analogs
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
KR100984085B1 (ko) 2002-10-22 2010-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 7-페닐 피라졸로피리딘 화합물
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
DE602004018637D1 (de) 2003-04-09 2009-02-05 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
DE102004037554A1 (de) * 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039507A1 (de) * 2004-08-14 2006-03-02 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkoxi-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1846410B1 (en) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
BRPI0609509A2 (pt) * 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
JP2009502959A (ja) * 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
GB0519245D0 (en) * 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
ES2560435T3 (es) 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
AU2008239754A1 (en) * 2007-04-11 2008-10-23 Merck Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
DK2209786T3 (da) 2007-10-05 2013-06-03 Verastem Inc Pyrimidinsubstituerede purinderivater
SI2266990T1 (sl) 2008-04-15 2013-01-31 Eisai R&D Management Co. Ltd. Spojina 3-fenilpirazolo(5,1-b)tiazola
US20110152313A1 (en) * 2008-06-20 2011-06-23 Macquarie University Synthesis of ageladine a and analogs thereof
FR2933982A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CN102428085B (zh) 2009-04-03 2015-07-15 维拉斯通股份有限公司 作为激酶抑制剂的嘧啶取代的嘌呤化合物
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013542202A (ja) 2010-10-01 2013-11-21 ブリストル−マイヤーズ スクイブ カンパニー Ｃｙｐ１７修飾因子として有用である置換ベンゾイミダゾールおよびイミダゾピリジン化合物
EP2638041B1 (en) 2010-11-12 2015-07-22 Bristol-Myers Squibb Company Substituted azaindazole compounds
WO2013049263A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
MX367341B (es) * 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
WO2015086519A1 (en) * 2013-12-09 2015-06-18 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of tnf activity
TWI663159B (zh) 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EP3079701B1 (en) 2013-12-11 2021-08-11 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP6645695B2 (ja) * 2014-10-14 2020-02-14 中尾　洋一 イミダゾピリジンアミン化合物、その製造方法及び用途
EP3233057A2 (en) 2014-12-18 2017-10-25 Genzyme Corporation Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
CN107922396B (zh) * 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
AU2018269947B2 (en) * 2017-05-15 2021-10-14 The Regents Of The University Of Michigan Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors
KR20210061202A (ko) * 2019-11-19 2021-05-27 일동제약(주) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
EP4452984A1 (en) * 2021-12-23 2024-10-30 Molecure S.A. Deubiquitinase inhibitors and methods of use thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015473A (en) * 1984-01-30 1991-05-14 Pfizer Inc. 6-(substituted)methylenepenicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US4859672A (en) * 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US5495010A (en) * 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
JPH03506033A (ja) * 1988-07-19 1991-12-26 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 置換フエニルトリアゾロピリミジン除草剤
AU618158B2 (en) * 1989-01-07 1991-12-12 Bayer Aktiengesellschaft New substituted pyrido(2,3-d)pyrimidines
FR2643903A1 (fr) * 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
GB8906168D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
DE3916469A1 (de) * 1989-05-20 1990-11-22 Basf Ag Sulfonamide
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5157026A (en) * 1989-05-30 1992-10-20 Merck & Co., Inc. Oxo-purines as angiotensin II antagonists
US5102880A (en) * 1989-05-30 1992-04-07 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
DE3921271A1 (de) * 1989-06-29 1991-01-03 Basf Ag Purinsulfonamide
US5145959A (en) * 1989-07-18 1992-09-08 Bayer Aktiengesellschaft Substituted pyrido (2,3-d) pyrimidines as intermediates
EP0416740A3 (en) * 1989-08-08 1991-08-28 Beecham Group P.L.C. Novel compounds with renin-inhibiting activity
EP0415886A3 (en) * 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
GB8927872D0 (en) * 1989-12-08 1990-02-14 Beecham Group Plc Pharmaceuticals
EP0434038A1 (en) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
US5587470A (en) * 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
EP0461040A1 (fr) * 1990-06-08 1991-12-11 Roussel Uclaf Dérivés de l'imidazole, leur procédé de préparation, les intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant
WO1991019715A1 (en) * 1990-06-15 1991-12-26 G.D. Searle & Co. 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
DE4023369A1 (de) * 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5210092A (en) * 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
CA2062558A1 (en) * 1991-03-08 1992-09-09 Prasun K. Chakravarty Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
CH681806A5 (et) * 1991-03-19 1993-05-28 Ciba Geigy Ag
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
TW274551B (et) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
US5332820A (en) * 1991-05-20 1994-07-26 E. I. Du Pont De Nemours And Company Dibenzobicyclo(2.2.2) octane angiotensin II antagonists
KR100207360B1 (ko) * 1991-06-14 1999-07-15 돈 더블유. 슈미츠 이미다조[1,5,-a]퀸옥살린
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
AU2338992A (en) * 1991-07-26 1993-03-02 G.D. Searle & Co. Carbonate-substituted imidazo(4,5-d) pyridazine compounds for treatment of cardiovascular disorders
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW300219B (et) * 1991-09-14 1997-03-11 Hoechst Ag
US5178997A (en) * 1991-09-20 1993-01-12 Eastman Kodak Company Process for the preparation of high chloride tabular grain emulsions (II)
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
US5330989A (en) * 1991-10-24 1994-07-19 American Home Products Corporation Heterocycles substituted with biphenyl-3-cyclobutene-1,2-dione derivatives
US5332814A (en) * 1991-11-12 1994-07-26 Ciba-Geigy Corporation Process for the preparation of carbacyclic nucleosides, and intermediates
US5176991A (en) * 1992-01-27 1993-01-05 Eastman Kodak Company Process of preparing for photographic use high chloride tabular grain emulsion
GB2263637A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists
JPH05213754A (ja) * 1992-02-03 1993-08-24 Kyowa Hakko Kogyo Co Ltd 抗潰瘍剤
IT1254798B (it) * 1992-02-18 1995-10-11 Snam Progetti Procedimento per il riavviamento dell'esercizio di una condotta contente fluidi ad alto valore di sforzo sterile e dispositivi per la sua realizzazione.
DE4207904A1 (de) * 1992-03-12 1993-09-16 Thomae Gmbh Dr K Substituierte benzimidazolylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH05287209A (ja) * 1992-04-09 1993-11-02 Hitachi Chem Co Ltd 蛍光標識用色素、蛍光標識用色素で標識された生物由来物質、及びそれらを含有する試薬
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
PT604657E (pt) * 1992-05-21 2000-04-28 Otsuka Pharma Co Ltd Derivado de diester fosfonico
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
EP0577558A2 (de) * 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
WO1994007910A1 (en) * 1992-09-28 1994-04-14 Research Corporation Technologies, Inc. New reagents for peptide couplings
TW251284B (et) * 1992-11-02 1995-07-11 Pfizer
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
GB2272899A (en) * 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
BR9307570A (pt) * 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv
AU673055B2 (en) * 1993-02-03 1996-10-24 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5374638A (en) * 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
DE4309969A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
CA2131134A1 (en) * 1993-09-17 1995-03-18 Gerhard Stucky Process for preparing imidazopyridine derivatives
CA2131680C (en) * 1993-09-17 2006-11-07 Gerhard Stucky Process for preparing imidazopyridine derivatives
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
US5498715A (en) * 1993-12-01 1996-03-12 Lonza Ltd. Process for preparing imidazopyridine derivatives
HU220423B (hu) * 1994-01-26 2002-01-28 Novartis Ag. Módosított oligonukleotidok
KR0151816B1 (ko) * 1994-02-08 1998-10-15 강박광 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법
KR970701182A (ko) * 1994-02-10 1997-03-17 스피겔 알렌 제이 벤조다이아제핀 수용체 부위의 작용물질 및 길항물질로서의 5-헤테로아릴인돌 유도체(5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists)
DE59510742D1 (de) * 1994-04-27 2003-08-14 Novartis Ag Nukleoside und Oligonukleotide mit 2'-Ethergruppen
US5424432A (en) * 1994-05-26 1995-06-13 Merck & Co., Inc. Process for the preparation of imidazolutidine
KR100263429B1 (ko) * 1994-06-06 2000-08-01 디. 제이. 우드 코르티코트로핀-방출 인자(crf) 길항 활성을 갖는 치환된 피라졸
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
KR0151819B1 (ko) * 1994-06-11 1998-10-15 강박광 신규의 피리딜 n-옥사이드로 치환된 피디딜이미다졸 유도체 및 그의 제조방법
EP0765327B1 (en) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
WO1996019478A1 (en) * 1994-12-19 1996-06-27 Novartis Ag 6'-substituted carbocyclic nucleosides
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
AU1592697A (en) * 1995-08-22 1997-03-19 Du Pont Merck Pharmaceutical Company, The Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors
DE19536891A1 (de) * 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
US6022978A (en) * 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
TR199900389T2 (xx) * 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists

Also Published As

Publication number Publication date
IL133800A0 (en) 2001-04-30
AU8181998A (en) 1999-01-25
NO996483D0 (no) 1999-12-27
WO1999001454A1 (en) 1999-01-14
NZ502642A (en) 2002-06-28
PL337888A1 (en) 2000-09-11
BR9810508A (pt) 2000-09-05
MY132871A (en) 2007-10-31
EE04280B1 (et) 2004-04-15
SK179899A3 (en) 2001-12-03
US6143743A (en) 2000-11-07
KR20010014431A (ko) 2001-02-26
JP2002507996A (ja) 2002-03-12
AU746706B2 (en) 2002-05-02
CN1268137A (zh) 2000-09-27
TW589309B (en) 2004-06-01
AR016307A1 (es) 2001-07-04
US6642230B2 (en) 2003-11-04
EP0994877A1 (en) 2000-04-26
HUP0100179A3 (en) 2002-12-28
HUP0100179A2 (hu) 2001-11-28
CA2294117A1 (en) 1999-01-14
HRP980375A2 (en) 1999-04-30
NO996483L (no) 2000-03-02
US20030114468A1 (en) 2003-06-19
US6362180B1 (en) 2002-03-26
NO316119B1 (no) 2003-12-15

Similar Documents

Publication Publication Date Title
EE04280B1 (et) Imidasopürimidiinid ja imidasopüridiinid neuroloogiliste häirete käitlemiseks
GB2305605B (en) Pipecolic acid derivatives for the treatment of neurological disorders
NO991381L (no) Kombinasjonsterapi for behandling av psykoser
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
IS5113A (is) Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
NO20003065D0 (no) Kombinasjon for effektiv behandling av impotens
NO20014674D0 (no) Fremgangsmåte for behandling av neurologiske og neuropsykiatriske forstyrrelser
BR9707922A (pt) Cafeína e clemastina para tratamento de distúrbios respiratórios
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
NO20010456L (no) Triazolopyridiner for behandling av trombose lidelser
EE200000391A (et) Triasiiniühendid kesknärvisüsteemihäirete raviks
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO982562D0 (no) Sammensetning for behandling av smerte
IL131347A0 (en) Treatment of skin disorders
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
NO994526L (no) Fremgangsmaate for stimulering av neural regenerering
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
NO986053D0 (no) Antikonvulsive derivater for behandling av psoriasis
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
NO962812D0 (no) Fremgangsmåte for behandling av nervebetennelse
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
UA25221A (uk) Спосіб лікуваhhя розладів цеhтральhої hервової системи

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

MM4A Lapsed by not paying the annual fees

Effective date: 20050702